Scholar Rock Holding Co. (NASDAQ:SRRK) General Counsel Sells $211,477.86 in Stock

Scholar Rock Holding Co. (NASDAQ:SRRK) General Counsel Junlin Ho sold 5,742 shares of the firm’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $36.83, for a total transaction of $211,477.86. Following the completion of the sale, the general counsel now owns 189,295 shares of the company’s stock, valued at $6,971,734.85. This trade represents a 2.94 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Junlin Ho also recently made the following trade(s):

• On Thursday, January 16th, Junlin Ho sold 9,039 shares of Scholar Rock stock. The stock was sold at an average price of $44.20, for a total transaction of $399,523.80.

Scholar Rock Price Performance

Shares of SRRK opened at $37.70 on Friday. The company has a market capitalization of $3.53 billion, a P/E ratio of -16.04 and a beta of 0.50. The company has a quick ratio of 3.88, a current ratio of 3.88 and a debt-to-equity ratio of 0.63. The firm has a 50 day moving average of $41.81 and a 200 day moving average of $28.51. Scholar Rock Holding Co. has a twelve month low of $6.76 and a twelve month high of $46.98.

Institutional Investors Weigh In On Scholar Rock

Several institutional investors and hedge funds have recently made changes to their positions in SRRK. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Scholar Rock by 21.6% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,895 shares of the company’s stock valued at $25,000 after acquiring an additional 514 shares in the last quarter. GAMMA Investing LLC increased its position in shares of Scholar Rock by 51.8% during the fourth quarter. GAMMA Investing LLC now owns 788 shares of the company’s stock valued at $34,000 after acquiring an additional 269 shares in the last quarter. Quarry LP increased its position in shares of Scholar Rock by 3,443.3% during the third quarter. Quarry LP now owns 4,500 shares of the company’s stock valued at $36,000 after acquiring an additional 4,373 shares in the last quarter. Global Retirement Partners LLC increased its position in shares of Scholar Rock by 584.7% during the fourth quarter. Global Retirement Partners LLC now owns 897 shares of the company’s stock valued at $39,000 after acquiring an additional 766 shares in the last quarter. Finally, Nisa Investment Advisors LLC grew its position in Scholar Rock by 1,321.8% in the 4th quarter. Nisa Investment Advisors LLC now owns 1,109 shares of the company’s stock worth $48,000 after purchasing an additional 1,031 shares during the period. Institutional investors own 91.08% of the company’s stock.

Analyst Ratings Changes

SRRK has been the subject of several recent research reports. Truist Financial lifted their target price on shares of Scholar Rock from $36.00 to $45.00 and gave the company a “buy” rating in a report on Monday, November 25th. HC Wainwright lifted their target price on shares of Scholar Rock from $40.00 to $50.00 and gave the company a “buy” rating in a report on Tuesday, November 26th. Finally, Wedbush reiterated an “outperform” rating and set a $47.00 target price on shares of Scholar Rock in a report on Wednesday, January 29th. Six investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $40.43.

Scholar Rock Company Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.